Fresenius Kabi USA, LLC recalls Naropin (ropivacaine hydrochloride Injection
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- Presence of Particulate Matter: Hair was found in products
- Products
-
- Naropin (ropivacaine hydrochloride Injection
- Company
- Fresenius Kabi USA, LLC
- Where it was sold
-
Nationwide within in the USA
Nationwide
- Units affected
- 92,600 vials
- About this recall
- Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05